Biomarkers are the order of the day—an endogenous signal flare that’s fired, perhaps even before actual disease onset, warning of impending illness. The problem for the clinician, and way before that, the researcher at the bench is how do you detect that tiny, diagnostically incandescent signal.
Spinal implant manufacturer Globus Medical may have to pay $16 million after a jury decided that...
Teva Pharmaceutical Industries Ltd. is buying MicroDose Therapeutx for $40 million to build its...
Metal-peptide complexes play an important role in understanding the mechanisms behind complex diseases at the molecular level. Peptides are good chelators for metal ions and can form important tools in the drug and medical device industries.
Valeant Pharmaceuticals will sell $1.75 billion in stock to help fund its $4.5 billion purchase of Bausch + Lomb, to cover fees and expenses related to the deal, and to repay or retire Bausch + Lomb's debt. Valeant agreed to buy Bausch + Lomb in a major expansion of its ophthalmology business.
Simultaneous, Formalin-Free Preservation of Tissue Biomarkers and Morphology for Biomarker Discovery and BiobankingJune 17, 2013 11:47 am | Webinars | Comments
In this webinar, PreAnalytix will introduce a new technology, the PAXgene Tissue System, which preserves tissue morphology, DNA, RNA, miRNA, proteins, and phosphoproteins in the same sample without cross-linking of biomolecules or damage to the tissue architecture or histomorphology.
The Supreme Court ruled that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and therefore challenged by federal officials in court.
Johnson & Johnson said that it has agreed to buy Aragon Pharmaceuticals Inc. for at least $650 million in cash, boosting its position in prostate drug development. The privately-held San Diego, company is focused on the development of drugs to treat hormonally-driven cancers.
Eli Lilly and Co. will pay Transition Therapeutics Inc. $7 million and take over the development of a potential diabetes treatment heading into mid-stage clinical testing. Transition could also receive up to $240 million in additional payments, plus royalties if the treatment is eventually approved and sold.
The Alabama State Supreme Court is reconsidering a decision allowing makers of name brand drugs to be held liable for injuries caused by generic versions that are made by different companies. The court will hold oral arguments in response to a request that the court reverse an opinion it issued in January.
As electronic medical records continue to debut in hospitals across the country, researchers are exploring ways to optimize the data hidden in clinical notes that could benefit the pharmaceutical community—by finding early signs of potentially harmful drug side effects.
Abbott Laboratories plans to buy back up to $3 billion of its common stock, replacing a finished $5 billion program that began before the health care company separated from its drug business. Abbott makes generic drugs, medical implants, and nutritional formula.
The Supreme Court handed Myriad Genetics Inc. a partial victory in a battle over the validity of patents underlying its test for genes linked to high risk of breast and ovarian cancer. The ruling likely will eventually benefit rivals, as well as doctors and patients wanting to determine the best course of treatment.
In a surprising new finding, a study has found a common molecular vulnerability in autism and fetal alcohol spectrum disorder. Both disorders have symptoms of social impairment and originate during brain development in utero. This damage may be reverseable, however.
By transferring four genes into mouse fibroblast cells, researchers have produced cells that resemble hematopoietic stem cells, which produce millions of new blood cells in the human body every day. These findings provide a platform for development of cell-replacement therapy.
Eli Lilly and Co. has stopped a mid-stage clinical trial of an experimental Alzheimer's disease drug because of potential side effects on patients' livers. The company stopped testing LY2886721 because of abnormal results in liver biochemical tests.
Developed for liquid nitrogen freezing and long-term cryogenic freezer storage, laboratory labeling specialists CILS have launched a computer printable durable label for ultra low temperatures, providing immediate permanent adhesion to all cyrovials, tubes, and liquid straws stored down to -196ºC.
Nanotechnology opens up a portal into living tissue that allows scientists to watch cancers spreading, and to determine which parts of a tumor should be targeted. Clinicians can then see where they need to improve on drug delivery to improve clinical outcome.